High Dose Atorvastatin Decreases Cellular Markers of Immune Activation Without Affecting HIV-1 RNA Levels: Results of a Double-blind Randomized Placebo Controlled Clinical Trial

Proteinuria, Creatinine Clearance, and Immune Activation in Antiretroviral‐Naive HIV‐Infected Subjects

(2009) Samir K. Gupta et al.   JOURNAL OF INFECTIOUS DISEASES

Activation and Coagulation Biomarkers Are Independent Predictors of the Development of Opportunistic Disease in Patients with HIV Infection

(2009) Alison J. Rodger et al.   JOURNAL OF INFECTIOUS DISEASES

Immunologic and Virologic Events in Early HIV Infection Predict Subsequent Rate of Progression

(2009) Anuradha Ganesan et al.   JOURNAL OF INFECTIOUS DISEASES

The macrophage: the intersection between HIV infection and atherosclerosis

(2009) Suzanne M. Crowe et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Interplay of Reverse Transcriptase Inhibitor Therapy and Gag p6 Diversity in HIV Type 1 Subtype G and CRF02_AG

(2008) Akinyemi I. Ojesina et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Failure of atorvastatin to modulate CSF HIV-1 infection: Results of a pilot study

(2008) J. C. Probasco et al.   NEUROLOGY

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

(2008) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy

(2008) Jeffrey A Johnson et al.   PLOS MEDICINE

The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells

(2007) Karin Mausner-Fainberg et al.   ATHEROSCLEROSIS

Relationship between T Cell Activation and CD4+T Cell Count in HIV‐Seropositive Individuals with Undetectable Plasma HIV RNA Levels in the Absence of Therapy

(2007) Peter W. Hunt et al.   JOURNAL OF INFECTIOUS DISEASES